000143004 001__ 143004
000143004 005__ 20240229112539.0
000143004 0247_ $$2doi$$a10.1097/SLA.0000000000002564
000143004 0247_ $$2pmid$$apmid:29064893
000143004 0247_ $$2ISSN$$a0003-4932
000143004 0247_ $$2ISSN$$a1528-1140
000143004 0247_ $$2altmetric$$aaltmetric:55566522
000143004 037__ $$aDKFZ-2019-00629
000143004 041__ $$aeng
000143004 082__ $$a610
000143004 1001_ $$aRahbari, Nuh N$$b0
000143004 245__ $$aTime of Metastasis and Outcome in Colorectal Cancer.
000143004 260__ $$a[S.l.]$$bOvid38850$$c2019
000143004 3367_ $$2DRIVER$$aarticle
000143004 3367_ $$2DataCite$$aOutput Types/Journal article
000143004 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661417695_31348
000143004 3367_ $$2BibTeX$$aARTICLE
000143004 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143004 3367_ $$00$$2EndNote$$aJournal Article
000143004 520__ $$aThe aim of this study was to evaluate outcomes of metastases at various time intervals after colorectal cancer (CRC) diagnosis.Earlier studies have indicated a short time interval between CRC diagnosis and distant metastases to be associated with poor prognosis. The majority of studies assessed outcome from CRC diagnosis or metastasis resection rather than from metastasis diagnosis and might be subject to immortal time bias.Patients in the population-based DACHS study were stratified: metastases at/within 1 month (immediate), 2 to 6 months (early), 7 to 12 months (intermediate), and >12 months (late) after CRC diagnosis. The primary endpoint was overall survival (OS) from metastasis diagnosis. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CI). HRs were adjusted for important confounders and immortal time.A total of 1027 patients were included. T4 (P < 0.0001) and node-positive tumors (P < 0.0001) were more frequent in the immediate group. Lung metastases (P < 0.0001) and single-site metastases (P < 0.0001) were more prevalent in the late group. In multivariable analysis, immediate metastases were not associated with poor OS compared to metastases at later time points (late vs immediate: HR 1.21; 95% CI, 0.98-1.48). Subgroup analyses revealed poor OS of late versus immediate metastases for females (1.45; 1.08-1.96), proximal colon cancer (1.54; 1.09-2.16), and N0 (1.46; 1.00-2.12) or N1 disease (1.88; 1.17-3.05).Immediate or early metastases are not associated with unfavorable outcome compared to late metastases. These findings challenge the current notion of poor outcome for CRC with immediate or early metastases.
000143004 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143004 588__ $$aDataset connected to CrossRef, PubMed,
000143004 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence$$b1$$eFirst author
000143004 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2
000143004 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3
000143004 7001_ $$aWeitz, Jürgen$$b4
000143004 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5
000143004 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$eLast author
000143004 773__ $$0PERI:(DE-600)2002200-1$$a10.1097/SLA.0000000000002564$$gVol. 269, no. 3, p. 494 - 502$$n3$$p494 - 502$$tAnnals of surgery$$v269$$x0003-4932$$y2019
000143004 909CO $$ooai:inrepo02.dkfz.de:143004$$pVDB
000143004 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143004 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143004 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143004 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143004 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000143004 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143004 9141_ $$y2019
000143004 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000143004 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143004 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143004 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143004 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143004 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143004 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN SURG : 2017
000143004 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143004 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143004 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143004 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143004 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143004 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143004 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN SURG : 2017
000143004 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000143004 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143004 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000143004 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000143004 980__ $$ajournal
000143004 980__ $$aVDB
000143004 980__ $$aI:(DE-He78)C070-20160331
000143004 980__ $$aI:(DE-He78)C120-20160331
000143004 980__ $$aI:(DE-He78)C020-20160331
000143004 980__ $$aI:(DE-He78)L101-20160331
000143004 980__ $$aUNRESTRICTED